Phase 1 Refractory B-cell Acute Lymphoblastic Leukemia Clinical Trials
4 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–4 of 4 trials
Recruiting
Phase 1Phase 2
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
T-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL+3 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 1
A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.33 enrolled8 locationsNCT06927466
Recruiting
Phase 1
CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma, RelapsedNon-Hodgkin's Lymphoma RefractoryRelapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Institute of Hematology and Blood Transfusion, Czech Republic10 enrolled1 locationNCT05054257
Recruiting
Phase 1Phase 2
Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL
Relapse/Refractory B-cell Acute Lymphoblastic Leukemia
Kara Yakhteh Tajhiz Azma Company5 enrolled1 locationNCT06635330